4.7 Article

Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2

期刊

BLOOD
卷 112, 期 5, 页码 1931-1941

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2008-03-143040

关键词

-

资金

  1. National Institutes of Health, Bethesda, MD [CA062242, GM071514]
  2. Robert A. Kyle Hematologic Malignancies Program (Mayo Clinic)

向作者/读者索取更多资源

Primary systemic amyloidosis (AL) is a rare monoclonal plasma cell (PC) disorder characterized by the deposition of misfolded immunoglobulin (Ig) light chains (LC) in vital organs throughout the body. To our knowledge, no cell lines have ever been established from AL patients. Here we describe the establishment of the ALMC-1 and ALMC-2 cell lines from an AL patient. Both cell lines exhibit a PC phenotype and display cytokine-dependent growth. Using a comprehensive genetic approach, we established the genetic relationship between the cell lines and the primary patient cells, and we were also able to identify new genetic changes accompanying tumor progression that may explain the natural history of this patient's disease. Importantly, we demonstrate that free lambda LC secreted by both cell lines contained a beta structure and formed amyloid fibrils. Despite absolute Ig LC variable gene sequence identity, the proteins show differences in amyloid formation kinetics that are abolished by the presence of Na2SO4. The formation of amyloid fibrils from these naturally secreting human LC cell lines is unprecedented. Moreover, these cell lines will provide an invaluable tool to better understand AL, from the combined perspectives of amyloidogenic protein structure and amyloid formation, genetics, and cell biology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Hematology

Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma

Aneta Mikulasova, Cody Ashby, Ruslana G. Tytarenko, Pingping Qu, Adam Rosenthal, Judith A. Dent, Katie R. Ryan, Michael A. Bauer, Christopher P. Wardell, Antje Hoering, Konstantinos Mavrommatis, Matthew Trotter, Shayu Deshpande, Shmuel Yaccoby, Erming Tian, Jonathan Keats, Daniel Auclair, Graham H. Jackson, Faith E. Davies, Anjan Thakurta, Gareth J. Morgan, Brian A. Walker

HAEMATOLOGICA (2020)

Article Oncology

Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

Juan-Jose Garces, Michal Simicek, Marco Vicari, Lucie Brozova, Leire Burgos, Renata Bezdekova, Diego Alignani, Maria-Jose Calasanz, Katerina Growkova, Ibai Goicoechea, Xabier Agirre, Ludek Pour, Felipe Prosper, Rafael Rios, Joaquin Martinez-Lopez, Pamela Millacoy, Luis Palomera, Rafael Del Orbe, Albert Perez-Montana, Sonia Garate, Laura Blanco, Marta Lasa, Patricia Maiso, Juan Flores-Montero, Luzalba Sanoja-Flores, Zuzana Chyra, Alexander Vdovin, Tereza Sevcikova, Tomas Jelinek, Cirino Botta, Halima El Omri, Jonathan Keats, Alberto Orfao, Roman Hajek, Jesus F. San-Miguel, Bruno Paiva

LEUKEMIA (2020)

Article Oncology

IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features

Surbhi Sidana, Daniel P. Larson, Patricia T. Greipp, Rong He, Ellen D. McPhail, Angela Dispenzieri, David L. Murray, Surendra Dasari, Stephen M. Ansell, Eli Muchtar, Wilson I. Gonsalves, Taxiarchis V. Kourelis, Marina Ramirez-Alvarado, Prashant Kapoor, S. Vincent Rajkumar, Martha Q. Lacy, Francis K. Buadi, Nelson Leung, Robert A. Kyle, Shaji K. Kumar, Rebecca L. King, Morie A. Gertz

LEUKEMIA (2020)

Article Oncology

Light chain amyloidosis induced inflammatory changes in cardiomyocytes and adipose-derived mesenchymal stromal cells

Torri L. Jordan, Khansaa Maar, Keely R. Redhage, Pinaki Misra, Luis M. Blancas-Mejia, Christopher J. Dick, Jonathan S. Wall, Angela Williams, Allan B. Dietz, Andre J. van Wijnen, Yi Lin, Marina Ramirez-Alvarado

LEUKEMIA (2020)

Letter Oncology

The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias

Linda B. Baughn, Zhuo Li, Kathryn Pearce, Celine M. Vachon, Mei-Yin Polley, Jonathan Keats, Eran Elhaik, Michael Baird, Terry Therneau, James R. Cerhan, P. Leif Bergsagel, Angela Dispenzieri, S. Vincent Rajkumar, Yan W. Asmann, Shaji Kumar

BLOOD CANCER JOURNAL (2020)

Letter Oncology

Prediction of immunomodulatory drugs (IMiDs) sensitivity in myeloma via determination of baseline anti-oxidative stress capacity

Luke Mountjoy, Sinto Sebastian, Tania Jain, Talal Hilal, Miguel Gonzalez-Velez, Marlene Girardo, Greg Ahmann, Jeremy Larsen, Leif Bergsagel, Rafael Fonseca

LEUKEMIA (2020)

Article Oncology

The mevalonate pathway is an actionable vulnerability oft(4;14)-positive multiple myeloma

Joseph Longo, Petr Smirnov, Zhihua Li, Emily Branchard, Jenna E. van Leeuwen, Jonathan D. Licht, Benjamin Haibe-Kains, David W. Andrews, Jonathan J. Keats, Trevor J. Pugh, Suzanne Trudel, Linda Z. Penn

Summary: This study revealed that t(4;14)-positive multiple myeloma cells depend on the mevalonate (MVA) pathway for survival and are sensitive to statin treatment. Statins induce apoptosis in t(4;14)-positive cells and synergize with bortezomib to enhance anti-tumor activity.

LEUKEMIA (2021)

Article Medicine, General & Internal

Targeting TMPRSS2 in SARS-CoV-2 Infection

Linda B. Baughn, Neeraj Sharma, Eran Elhaik, Aleksandar Sekulic, Alan H. Bryce, Rafael Fonseca

MAYO CLINIC PROCEEDINGS (2020)

Article Hematology

Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression

Vikas A. Gupta, Benjamin G. Barwick, Shannon M. Matulis, Ryosuke Shirasaki, David L. Jaye, Jonathan J. Keats, Benjamin Oberlton, Nisha S. Joseph, Craig C. Hofmeister, Leonard T. Heffner, Madhav Dhodapkar, Ajay K. Nooka, Sagar Lonial, Constantine S. Mitsiades, Jonathan L. Kaufman, Lawrence H. Boise

Summary: This study found that Venetoclax sensitivity is closely associated with the expression of B-cell genes and genomic features identified in transposase-accessible chromatin sequencing, and there are potential novel biomarkers associated with Venetoclax sensitivity.
Review Oncology

Plasma cell leukemia: A review of the molecular classification, diagnosis, and evidenced-based treatment

Krisstina Gowin, Sheri Skerget, Jonathan J. Keats, Joseph Mikhael, Andrew J. Cowan

Summary: Plasma cell leukemia, whether primary or secondary, is a rare and aggressive blood disorder with poor survival rates despite effective therapies. Recent molecular studies using gene expression profiling and whole exome sequencing have provided new insights into the disease, potentially leading to improved prognosis and treatment strategies.

LEUKEMIA RESEARCH (2021)

Article Multidisciplinary Sciences

Patient similarity network of newly diagnosed multiple myeloma identifies patient subgroups with distinct genetic features and clinical implications

Sherry Bhalla, David T. Melnekoff, Adolfo Aleman, Violetta Leshchenko, Paula Restrepo, Jonathan Keats, Kenan Onel, Jeffrey R. Sawyer, Deepu Madduri, Joshua Richter, Shambavi Richard, Ajai Chari, Hearn Jay Cho, Joel T. Dudley, Sundar Jagannath, Alessandro Lagana, Samir Parekh

Summary: MM-PSN is the first multiomics patient similarity network for multiple myeloma, accurately dissecting the genetic and molecular landscape of the disease and identifying 12 distinct patient subgroups. These subgroups provide important information for patient prognosis and clinical management.

SCIENCE ADVANCES (2021)

Article Oncology

Assessing Patient-Reported Financial Hardship in Patients With Cancer in Routine Clinical Care

Sandeep S. Voleti, Rahma Warsame, Carolyn Mead-Harvey, Sikander Ailawadhi, Atul Jain, Rafael Fonseca, Joan M. Griffin, Nandita Khera

Summary: This study presents a standardized approach to describe the prevalence and predictors of financial hardship (FH) in cancer patients and examines its association with survival. It highlights the need for further research to develop care pathways for patients at high risk of poor financial and clinical outcomes.

JCO ONCOLOGY PRACTICE (2022)

Review Oncology

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Rafael Fonseca, Diana Tran, Alyshia Laidlaw, Emily Rosta, Manvir Rai, Joana Duran, Eric M. Ammann

Summary: This systematic literature review aimed to understand the impact of disease progression, line of therapy, and clinical response on health-related quality of life in multiple myeloma patients. Through multiple rounds of screening, 41 studies were included, indicating that disease progression and increasing lines of therapy were associated with worsened patient HRQoL, while increasing depth of response was associated with improved patient HRQoL.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2023)

Review Oncology

Chromosome 1q21 abnormalities in multiple myeloma

Timothy M. Schmidt, Rafael Fonseca, Saad Z. Usmani

Summary: +1q chromosome gain is common in multiple myeloma, often seen as a poor prognostic marker but not uniformly adopted as high-risk. Controversy exists regarding its importance, with many genes at the 1q21 locus proposed to cause resistance to therapy.

BLOOD CANCER JOURNAL (2021)

Article Oncology

Economic burden of disease progression among multiple myeloma patients who have received transplant and at least one line of therapy in the US

Rafael Fonseca, May Hagiwara, Sumeet Panjabi, Emre Yucel, Jacqueline Buchanan, Thomas Delea

Summary: The impact of disease progression on healthcare resource utilization and costs among multiple myeloma patients who have undergone stem cell transplant and systemic anti-myeloma therapy is significant.

BLOOD CANCER JOURNAL (2021)

暂无数据